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Abstract 
Background and Purpose: Endovascular treatment of intracranial aneurysms has 
substantially developed in the past two decades. The aim of the present review is to 
evaluate some of the most impactful determinants of clinical outcome with the objective 
of projecting a more concise standpoint on endovascular treatment.  
Methods: A comprehensive review of literature from 1968 to 2016 was performed, 
reporting on relevant contributing factors to prognosis related to endovascular approach 
of intracranial aneurysms.  
Results:  The PHACES score and the Unruptured Intracranial Aneurysm Treatment 
Score both have limitations and need further evaluation. A recommendation has been 
made for the use of PAASH to the detriment of the most frequently used WFNS scale. 
The treatment of patients admitted more than 72 hours after haemorrhage can be 
delayed, if the estimated risk of rebleeding is low. The preferred protocol should focus 
on early resuscitation and stabilization followed by safe transfer rather than a 
hyperacute transfer paradigm. Thromboembolic complications and intraoperative 
rupture rates associated with coiling alone were 7.3% and 2.0% for unruptured 
aneurysms, and 13.3% and 3.7% for ruptured aneurysms. Balloon-Assisted Coil 
Embolization allows for optimal coil packing, particularly in the aneurysm neck and 
fundus. Pipeline Embolization Device was associated with a high aneurysm occlusion 
rate and a rate of adverse events comparable to those of more conventional techniques. 
Long-term durability and safety still remain to be proved by larger series and after 
prolonged follow-up with both the Surpass Flow Diverter and Flow-Redirection 
Endoluminal Device. Initial results associated Woven Endobridge device with complete 
and adequate occlusion rates of 27% and 59% respectively, that increased significantly 
at a mean follow up time of 7 months. 
Conclusions:  Given the development of new technologies for the treatment of 
intracranial aneurysms, the field of neurovascular intervention is only likely to expand 
further.  Supplementary randomized controlled trials are essential for proper outcome 
assessment.
 
Key words: endovascular; intracranial; subarachnoid; hemorrhage; treatment; aneurysms; embolization; flow; 
disrupter; diverter; 
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Abbreviations and Acronyms 
AES = Aneurysm Embolization System; ATENA = Analysis of Treatment by Endovascular approach of Non 
ruptured Aneurysms; AOR = Aneurysm Occlusion Rate; BACE = Balloon-Assisted Coil Embolization; CARAT = 
Cerebral Aneurysm Rerupture After Treatment; CLARITY = Clinical and Anatomical Results in the Treatment of 
Ruptured Intracranial Aneurysms; DSA = Digital Subtraction Angiography; EVT = endovascular treatment; FDDs = 
Flow Diverter Devices; FRED = Flow-Redirection Endoluminal Device; GCS = Glasgow Coma Score; GDC = 
Guglielmi Detachable Coil; IA = intracranial aneurysm; IPH = Intraparenchymal Hemorrhage; ISAT = International 
Subarachnoid Aneurysm Trial; MR = Magnetic Resonance; PAASH = Prognosis on Admission of Aneurysmal 
Subarachnoid Haemorrhage; PAO = Parent Artery Occlusion; PED = Pipeline Embolization Device; SACE = Stent-
Assisted Coil Embolization; SAH = subarachnoid hemorrhage; SFD = Silk Flow-Diverter; TIA = Transient Ischemic 
Attack; UIAs = unruptured intracranial aneurysms; UIATS = Unruptured Intracranial Aneurysm Treatment Score; 
WEB = Woven Endobridge; WFNS = World Federation of Neurological Surgeons Scale;  
 
Resumo 
Contexto e finalidade: O tratamento endovascular de aneurismas intracranianos 
desenvolveu-se substancialmente nas últimas duas décadas. A finalidade desta revisão é 
avaliar alguns dos determinantes com maior impacto no resultado clínico com o 
objectivo de dar projeção a um ponto da situação conciso no tratamento endovascular. 
Métodos: Efetuou-se uma revisão ampla da literatura desde 1968 a 2016, registando os 
fatores relevantes que contribuíram para o prognóstico relativamente à abordagem 
endovascular dos aneurismas intracranianos. 
Resultados: Tanto a gradação do PHACES como a gradação do Tratamento do 
Aneurisma Intracraniano sem ruptura têm limitações e precisam de mais avaliação. Tem 
sido recomendado o uso do PAASH em detrimento da escala WFNS, que é a mais 
frequentemente usada. O Tratamento de doentes admitidos mais do que 72 horas depois 
da hemorragia  pode ser adiado se for baixo o risco de novo sangramento. O protocolo 
preferido deverá ter o enfoque numa ressuscitação  e estabilização prévias seguidas de 
uma transferência segura em vez do paradigma de uma transferência hiperaguda. 
Complicações tromboembólicas e taxas de ruptura intraoperatória associadas ao coiling 
foram 7.3 % e 2.0 % em aneurismas não-rotos e 13.3% e 3.7% em aneurismas rotos. 
Coiling assistido por balão permite uma densidade de empactamento do coil optima, 
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particularmente no colo e fundo dos aneurismas. O Pipeline Embolization Device está 
associado a uma taxa de oclusão alta e a uma taxa de eventos adversos comparáveis a 
técnicas mais convencionais. A durabilidade e a segurança do Surpass Flow Diverter e 
do Flow-Redirection Endoluminal Device necessitam de comprovação por estudos 
amplos e de seguimento prolongado. Resultados iniciais do Woven Endobridge 
mostram taxas de oclusão completa e adequada de 27% e 59% respectivamente, que 
aumentam significativamente no seguimento a 7 meses.  
Conclusões: Dado o desenvolvimento das novas tecnologias no tratamento  dos 
aneurismas intracranianos, o campo da intervenção neurovascular está em clara 
expansão. São essenciais ensaios suplementares, randomizados e controlados, para uma 
avaliação adequada dos resultados. 
 
Introduction 
We have bare witness, in the past couple of decades, to the astonishing evolution 
of the endovascular treatment (EVT) of intracranial aneurysms (IAs), from a promising 
new technology to a front-line therapy based on advanced disease and anatomy-specific 
devices enabling a minimally invasive approach. These devices have themselves 
undergone profound changes transitioning from embolization coils to other implantable 
devices, adjunctive intracranial stents and ultimately to “stand-alone” stent-like devices 
(David Fiorella, 2008). Alongside these changes, new techniques (such as 3D 
angiography) and improvements in navigation and occlusion materials have enabled 
endovascular therapists to treat increasingly difficult, complex-shaped and wide based 
aneurysms, improving safety, efficacy and feasibility of EVT (Mitsos et al., 2013). The 
paradigm of treatment has shifted through time from techniques targeting merely the 
occlusion of the aneurysm sac to those designed also to achieve a durable physiological 
reconstruction of the parent vessel. Conversely, due to this relative infancy of EVT, a 
great deal of important questions remain to be answered, particularly regarding long 
term clinical outcome (Currie et al., 2011). This review intends to elaborate on some of 
the most important and influential issues relevant to the EVT clinical outcome, 
sanctioning a clearer decision making and a more concise understanding of the 
capability and limitations of this treatment modality.  
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Methods 
A comprehensive review of the literature from 1968 to 2016 was performed, reporting 
on relevant contributing factors related to endovascular approach of IAs. A total of 114 articles, 
all in the English language, were included base on relevance using PubMed, MEDLINE, 
Embase and b-on (Online Knowledge Library) search engines. For the search strategy, the 
keywords “ endovascular”, “treatment”, “Intracranial”, “aneurysms”, “embolization”, “LUNA”, 
“BACE”, “unruptured”, “ruptured”, “timing”, “ coil”, “stent”, “FRED”, “surpass”, “PED”, 
“Woven Endobridge”, “silk”, “disrupter”, “diverter”  with combinations and synonyms were 
used. “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly 
Work in Medical Journals (ICMJE 2015)” were taken into consideration.    
 
Management 
Management of IAs relies heavily on the correct assessment of the lesion since 
different types may require drastically different treatment methodologies. IAs can thus 
be broadly subdivided into two main approach categories: ruptured (associated with 
subarachnoid hemorrhage [SAH], intraparenchymal hematoma and an intraventricular 
hemorrhage) and those that remain unruptured (David Fiorella, 2008).  
 
Unruptured Intracranial aneurysms  
Through autopsy exams and catheter angiography, unruptured intracranial 
aneurysms (UIAs) have been known to exist for quite some time, but their true 
prevalence has only begun to emerge more recently with the widespread use of non-
invasive angiograms (Rabinstein, 2013). A recent systematic review and meta-analysis 
reported on 83 population studies including 1450 UIAs in 94 912 patients from 21 
countries. The overall prevalence in a population without comorbidity, with a mean age 
of 50 years, and consisting of 50% men was estimated to be 3.2% (Vlak et al., 2011). 
Despite generally being asymptomatic until rupture, UIAs can manifest as they grow 
and cause compression of adjacent brain structures. Middle cerebral artery aneurysms 
are known to cause hemiparesis, visual field defect, or seizures; posterior 
communicating artery or basilar artery aneurysms may lead to third cranial nerve palsy; 
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cavernous sinus aneurysms can trigger a cavernous sinus syndrome, and basilar 
aneurysms at times compress the brainstem. Rarely can embolus from the aneurysmal 
sac cause transient ischemic attack or cerebral infarction due to distal embolization 
(Ajiboye et al., 2015). The rational to treat an UIA is to prevent the rupture and its 
consequences as well as to address the symptoms; however, the indications to treat an 
UIA are complicated by limitations in our current knowledge of their natural history. 
Age and life expectancy of the patient, estimated risk of rupture, risk of complications 
attributed to the preventive treatment, and the level of anxiety caused by the awareness 
of having an aneurysm are critical aspects when considering UIA treatment (Etminan et 
al., 2016).  
The PHACES score is a model developed to aid the prediction of the risk of 
rupture of incidental intracranial aneurysms (Greving et al., 2014). Based on 
prospectively collected data from 6 cohort studies on risk of UIA rupture, it entails 
absolute risk of rupture for the first five years after initial aneurysms detection using 
both patient related predictors (age, hypertension, history of subarachnoid haemorrhage 
from another aneurysm and geographical region) and aneurysm related predictors 
(aneurysm size and location). Individual patient data from 8382 participants was 
systematically reviewed and submitted to pooled analysis with subarachnoid 
haemorrhage as outcome (230 had a subarachnoid haemorrhage during follow-up). 
Predictors were assessed with Cox proportional-hazard regression analysis, and 
cumulative rupture rates were analyzed with Kaplan-Meier curves/survival analysis. 
The mean observed one-year risk of aneurysm rupture was 1.4% and the five-year risk 
was 3.4%. Sex, smoking status at time of aneurysm detection, and presence of multiple 
aneurysms had limited predictive value on risk of rupture. The estimated five year 
absolute risk of aneurysm rupture, when studying populations from North America and 
Europe (Finland excluded), ranged from 0.25% in younger patients (<70 years old) with 
small-sized (<7mm) internal carotid artery aneurysm and no vascular risk factors 
associated, to over 15% in older patients (≥70 years of age) with hypertension, giant-
sized aneurysms (20mm) of the posterior circulation with a history of subarachnoid 
haemorrhage. Finnish people had a 3.6-times increased risk of aneurysm rupture by 
comparison with populations from other European countries and North America, while 
Japanese people had a 2.8-times increased risk (Greving et al., 2014). This prediction 
score had, however, significant limitations. Some subgroups may have been 
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underrepresented, such as familial aneurysms patients or young smokers. Limited long-
term follow up makes it so that the applicability of the score cannot go beyond the 
initial 5 years after UIA detection. Moreover, some known or suggested to be risk 
factors (e.g.: cigarette smoking; drug or alcohol use; clinical or radiologic signs of mass 
effect (Nima Etminan et al., 2015; Matsumoto et al., 1999)) for UIA rupture in case-
control studies could not be included in the PHACES score, not because they were not 
important risk factors for aneurysm rupture in isolation, but because these factors had no 
added value to the prediction of aneurysm rupture beyond the six predictors already 
used in the risk score. Finally, a clinician recommendation for treatment should also 
take into consideration the inherent risk of the intervention itself, which is not accounted 
for in the PHACES score (N. Etminan et al., 2015; Greving et al., 2014).  
These predictive restrictions in the PHACES score and the high level of 
variation among clinicians about the individual management of UIA patients laid 
grounds for alternative and newer treatment scores, such as the UIATS (Unruptured 
Intracranial Aneurysm Treatment Score) (N. Etminan et al., 2015). The aim was to 
objectively quantify consensus data on factors which, taken into consideration by 
specialists, are relevant for proper UIA management and to achieve agreement on 
UIATS based recommendations amongst specialists. Key factors for clinical decision 
making regarding UIA management were developed based on relevance rating data 
using the Delphi method and are sub grouped and risk scaled in correlation to the 
aneurysm, to the patient and to the treatment modality. To calculate a management 
recommendation for an UIA, the number of points corresponding to each patient, 
aneurysms or treatment related feature on both management columns of the scoring 
form (labeled “in favor of UIA repair” and “in favor of UIA conservative 
management”) is added up. A numeric difference between these two columns of three 
points or greater should indicate an individual management recommendation (either 
aneurysm repair or conservative approach); Cases that have similar aneurysm treatment 
and conservative management scores (two or less points in difference) have a “not 
definite recommendation” and both approaches could be supported by additional factors 
not included in the development of UIATS. This model merits to include many different 
important decision making factors disregarded in previous observational studies, such as 
young age or life expectancy, coexistent modifiable or nonmodifiable risk factors, 
coexistent morbidities, morphologic UIA features or relevance of clinical symptoms 
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related to UIAs (N. Etminan et al., 2015). This treatment score also has its limitations. 
First, it requires more baseline characteristics than the PHASES score and therefore its 
applicability is marginally more time consuming. Second, the consensus derived data 
used in this UIATS, which includes some subjective contributions from experts 
experience, does not replace evidence and should rather be seen as a way to 
complement it. Third, the “population” of specialists used to elaborate this score could 
hardly ever be claimed to be representative of the general “community of UIA experts”.  
Finally, pooled data from meta-analysis was incorporated to define treatment risk 
percentages into this model which may uncover deviation results due to surgeons or 
neuroradiologists experience or even treatment modality. UIATS model remains to be 
prospectively tested with empirical data regarding its applicability and clinical accuracy 
(N. Etminan et al., 2015). 
 
Ruptured Intracranial Aneurysms 
The rupture of an IA is a diagnostic and therapeutic emergency almost always 
treated, provided that the patient is neurologically and physiologically well enough to 
undergo the procedure. Management entails a multidisciplinary team of 
neuroradiologists, neurosurgeons and neurology intensive care physicians (Anxionnat et 
al., 2015). Spontaneous subarachnoid hemorrhage (SAH) is a devastating event 
triggered by rupture of an intracranial aneurysm in 80%–90% of cases; it entails 
significant morbidity and mortality and causes serious systemic and neurologic 
complications. Rebleeding is the most severe complication in terms of mortality and 
morbidity and also the most prevalent with up to 80% incidence rate (Kirkpatrick, 2002; 
Rivero Rodríguez et al., 2014). The mortality for untreated aneurysmal SAH is as high 
as 50%-60% in the first months, primarily because of rerupture (Westerlaan et al., 
2011). Within 6 months, from those patients who recover from the first bleeding 
episode, roughly one third left with an untreated aneurysm will die from recurrent 
bleeding (Steiner et al., 2013). 
Patient Assessment 
 Neurological condition of the patient on admission, age, and the amount of 
extravasated blood seen on CT scans are the three main variables contributing the 
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most to aneurysmal SAH clinical outcome. The level of consciousness evaluated 
within the neurologic condition is the most influential determinant for SAH clinical 
outcome, and since neurologic condition is likely to evolve during clinical course 
after a SAH, a reliable and valid grading system enabling unequivocal and 
understandable documentation is of the outmost importance (Steiner et al., 2013). 
Developing scales to clinically grade patients with SAH and measure the severity of 
initial neurological injury, providing prognostic information regarding outcome, guiding 
treatment decisions, and standardizing patient assessment across medical centers, has 
been an imperative and demanding task (Rosen et al., 2005). Most grading scales 
translate an attempt to convert a qualitative impression of SAH severity into a 
quantitative measurement with the purpose of early prognosis estimation. With this 
background, several grading systems have been proposed, such as the Fisher Scale, 
the Hunt and Hess Scale, the Glasgow Coma Score (GCS), and the World Federation of 
Neurological Surgeons (WFNS) Scale (Fisher et al., 1980; Hunt et al., 1968; "Report of 
World Federation of Neurological Surgeons Committee on a Universal Subarachnoid 
Hemorrhage Grading Scale," 1988; G. Teasdale et al., 1974). The Fisher Scale is based 
on the relationship between the amount and distribution of subarachnoid blood detected 
by computerized tomography and the later development of cerebral vasospasm (Fisher 
et al., 1980) (Annex table 1). Clinical assessment and grading of SAH severity is most 
commonly determined using either Hunt and Hess classification or the (WFNS) scale 
(D’Souza, 2015) (Annex table 2 and 4).  Delaying intervention and proceeding with 
conservative therapy until the patient’s condition spontaneously improves to a more 
favorable grade has been advocated for high grade Hunt and Hess patients because of 
their poor prognosis (Bracard et al., 2002; G. M. Teasdale et al., 1988). However, 
Hunt and Hess scales reliability and validity have shown issues related to the unclear 
definition of neurological status. A committee of the WFNS, recognizing the advantage 
of a reasonable inter-observer agreement provided by the GCS, proposed a grading 
scale of five levels, essentially based on the GCS, with focal deficits making up one 
extra level for patients with a GCS of 14 or 13 (Steiner et al., 2013) (Annex table 3). 
The initial clinical presentation of patients with SAH is presumed to be the most 
significant predictor of the final outcome. Within this new system, WFNS high grades 
remained strongly predictive for extremely poor outcome. Acute interventional 
therapy of patients with high grade WFNS, by reason of a poor predetermined 
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prognosis, is frequently delayed until any spontaneous improvement, with or without 
an external ventricular drainage (Wostrack et al., 2013). Another grading scale, the 
Prognosis on Admission of Aneurysmal Subarachnoid Haemorrhage (PAASH), based 
solely on the GDS, showed good prognostic value for patient outcome and an even 
better gradual increase in the proportionate distribution of patients with poor outcome 
per each increasing PAASH grade than the WFNS scale (van Heuven et al., 2008) 
(Annex table 5). This led the European Stroke Organization Guidelines for the 
Management of Intracranial Aneurysms and Subarachnoid Haemorrhage to make a 
recommendation for the use of PAASH in detriment to the most frequently used WFNS 
scale (Steiner et al., 2013). 
 
Table 1 - Summary of Relevant Prognostic Factors in ruptured aneurysms 
Factor Purpose 
Correlation 
according to 
grading 
Class of 
Evidence 
Or 
Suggested 
Power 
Overall inter-rater 
reliability – (κ) 
Evaluated signs 
(assumed as signs of 
SAH) 
Reference 
Hunt and Hess 
Scale 
- Aid neurosurgeons in 
deciding on the 
appropriate time after 
SAH at which the patient 
should be operated on  
- Assess the severity of 
SAH 
The higher the grade, 
the poorer the 
prognosis 
 
N/A 
 
 
0.42 
- intensity of meningeal 
inflammatory reaction 
- severity of neurological 
deficit 
- level of arousal 
Rosen et al., 
2005 
Fisher Scale 
- Predict cerebral 
vasospasm after SAH 
The higher the grade, 
the poorer the 
prognosis 
4 
 
0.90 
- blood visualized on initial 
computed tomography (CT) 
scanning 
Rosen et al., 
2005 
Glasgow Coma 
Score (GCS) 
- grading level of 
consciousness 
The lower the grade, 
the poorer the 
prognosis 
 
 
0.69 
- eye opening 
- verbal response 
- motor response 
Rosen et al., 
2005 
World 
Federation of 
Neurological 
Surgeons Scale 
(WFNS) 
- Include five grades 
- Be based on the GCS 
- Acknowledge the 
presence of a focal 
neurological deficit 
 
The higher the grade, 
the poorer the 
prognosis 
 
 
0.60 
- eye opening 
- verbal response 
- motor response 
- presence of a focal 
neurological deficit 
Rosen et al., 
2005 
PAASH 
- Group GCS grades in 
order to better assess 
SAH prognosis 
The higher the grade, 
the poorer the 
prognosis 
N/A 0.64 
- eye opening 
- verbal response 
- motor response 
Steiner et al., 
2013 
 
* κ = 1 corresponds to complete agreement between raters, and a κ = 0 corresponds to no agreement between raters (κ values are 
often reported to measure the inter-rater reliability of grading systems or of various diagnostic tests. 
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Treatment timing 
After patient assessment, it is imperative to occlude the aneurysm promptly 
given the recurrence risk. Despite the promising results obtained with the endovascular 
treatment of ruptured intracranial aneurysms, reliable data is still scarce on the effects of 
the timing of this approach on clinical outcome (Consoli et al., 2013). Although 
recurrent hemorrhage can occur at any time after the initial SAH in patients with both 
good and poor clinical grades, the incidence of a recurrent hemorrhage is highest within 
24 hours of SAH and increases with the severity of the clinical grade (Park et al., 2015). 
Nonetheless, in a series consisting of 510 patients (167 M, 343 F; mean age 56.45 years) 
with 557 ruptured intracranial aneurysms, hyper-early timing (<12 hours) of the neuro-
interventional procedure was not significantly related to a good clinical outcome. In 
fact, it seemed to show an inverse correlation with a good clinical outcome (Consoli et 
al., 2013). Another study aiming to elucidate the effect of treatment timing on 
procedural clinical outcomes, compared two groups of patients treated before (early 
approach) and after 48h, concluded that EVT should be performed as quickly as 
possible, without considering the latency between the onset of symptoms and the time 
of arrival at the hospital, given the fact that it did not increase the peri-procedural 
morbidity and reduced the risk of pre-treatment rebleeding (Baltsavias et al., 2000). In 
another study published in 2011, two groups of patients treated before (ultra-early 
treatment) and after (early treatment) 24 hours, presented results showing better 
outcome at six months in the ultra-early approach group (within 24 hours) (Phillips et 
al., 2011). Because the advantages of ultra-early treatment are still controversial and 
currently we have not reached a consensus on this issue, guidelines propose aneurysms 
should be occluded promptly, within 72 hours and if possible 48 hours (Anxionnat et 
al., 2015; Matias-Guiu et al., 2013; Oudshoorn et al., 2014). The treatment of patients 
admitted more than 72 hours after haemorrhage can be delayed, if the estimated risk of 
rebleeding is low, but it should be done always as early as possible and never more than 
10 days (Dorhout Mees et al., 2012; Matias-Guiu et al., 2013). 
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Aneurysmal SAH 
Admission < 72h Admission > 72h 
Is there a high risk of reebleeding? (clinical 
status , aneurysm size, sentinel headache, 
blood pressure...) 
Immediate treatment Yes No 
Programmed treatment  
(as early as possible) 
              (Matias-Guiu et al., 2013) 
 
Treatment Centers 
Admission and treatment in low versus high-volume hospitals has been 
considered to be an important aspect in optimizing care for SAH patients. Higher 
volume tertiary/quaternary specialized centers allow rapid access to specialized 
treatment improving clinical outcome and reducing mortality (Nuno et al., 2012; Wilson 
et al., 2015). Even though recommendations have been made so that low-volume 
hospitals consider transferring patients with SAH to higher volume centers with 
specialized services, there is currently a wide variance in transfer practices between 
institutions owing to the uncertainty related to optimal time frame for transfer and to the 
absence of specific recommendations to guide the process. Complications derived from 
delayed transfer include a higher risk of secondary brain injury from hemodynamic and 
respiratory compromise outside of an intensive care unit, rebleeding and delayed 
implementation of appropriate neurosurgical treatment. A retrospective cohort study 
was performed to determine how transfer time and subarachnoid grade would affect the 
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occurrence of symptomatic vasospasm, functional outcome, and mortality of transferred 
patients versus directly admitted patients. Transfer time was concluded not  to be 
associated with the occurrence of symptomatic vasospasm, 12-month outcome, 
rebleeding, or 12-month mortality, which seems to agree with studies suggesting that 
ultra-early treatment does not appear to be beneficial (Oudshoorn et al., 2014; Wilson et 
al., 2015). Thus, factors related to the acute to subacute management of SAH may play 
a more important role than the hyperacute management in terms of overall prognosis of 
high-grade patients. Early resuscitation and stabilization followed by safe transfer rather 
than a hyperacute transfer paradigm should be the preferred protocol; nevertheless, 
transfer time ought to be minimized as much as possible with a goal of less than 
8 hours, so that time to definitive treatment is not delayed (Wilson et al., 2015). 
 
Therapeutic modalities 
Coiling 
 Guglielmi and his co-workers started, in 1991, a new era in the EVT of ruptured 
IAs with the introduction of an electrically detachable coil system (GDC – Guglielmi 
Detachable Coil) which was pushed into the aneurysm sac through a microcatheter, 
repositioned, retrieved, or replaced by different sized coil until an acceptable result was 
achieved (Guglielmi et al., 1991). Initially, endovascular techniques were used for 
aneurysms considered inoperable or in patients whose previous surgical treatment had 
failed (Guglielmi et al., 1992). Since the first GDCs and platinum detachable coils, the 
standard coil embolization techniques have been developed much further resulting in 
greater number of patients being managed with endovascular coiling (Shin et al., 2015). 
Initial large series showed acceptable mortality (≈2%) and morbidity (between 4% and 
9%) (Cognard et al., 1998; Vinuela et al., 1997). Subsequent larger series came to 
confirm feasibility of aneurysm coiling (96.9% in ruptured aneurysms and 94.0% in 
unruptured aneurysms) along with acceptable procedural mortality (1.4% in ruptured 
aneurysms and 1.7% in unruptured aneurysms) and morbidity rates (8.6% in ruptured 
and 7.7% in unruptured aneurysms) (Gallas et al., 2008; Gallas et al., 2005).  
The publication of the International Subarachnoid Aneurysm Trial (ISAT) 
demonstrated improved one-year clinical outcomes for patients with ruptured 
 
16 
 
intracranial aneurysms treated with endovascular coiling compared to surgical clipping 
(A. Molyneux et al., 2002). The trial showed that for 2,143 SAH patients eligible for 
both surgery and endovascular coiling, recruited between 1994 and 2002, randomized 
allocation to coiling was associated with better one-year clinical outcomes defined as 
survival without dependency, demonstrating that coiling should be adopted as the first-
line treatment for ruptured aneurysms, at least for patients with the types of lesions 
included in the ISAT (Darsaut et al., 2013). The management of unruptured intracranial 
aneurysms (UIA), however, remains challenging. In untreated patients, the risk of 
aneurysm rupture is multifactorially mediated and has to be weighed against the risk 
associated with preventive aneurysm obliteration consisting of either microsurgical 
clipping (MS) or endovascular aneurysm occlusion (Brundl et al., 2016). Although for 
unruptured aneurysms (UIA) a direct comparison between EVT and surgery is not yet 
available, EVT has also been widely used in this subgroup (L. Pierot et al., 2013).  
Two large, prospective, multicenter series were conducted in order to analyze 
thromboembolic complications and intraoperative rupture (the two most frequent 
aneurysm coiling complications), in ruptured aneurysms (Cognard et al., 2011) and 
unruptured aneurysms (Laurent Pierot et al., 2008). Laurent Pierot presented the 
unruptured aneurysms series showing thromboembolic complications and intraoperative 
rupture rates associated with coiling alone of 7.3% and 2.0% respectively. For both 
specific complications, no clinical worsening was observed in approximately half the 
cases, but the mortality rate was higher after intraoperative rupture (16.7%) than after 
thromboembolic complications (4.1%) (L. Pierot et al., 2013). In ruptured aneurysms, 
the rates of thromboembolic complications and intraoperative rupture were as high as 
13.3% and 3.7%, respectively (Cognard et al., 2011).  Intravenous heparin for 
anticoagulation and aspirin as an antiplatelet agent have been adopted for unruptured 
aneurysms and, in some cases, also for ruptured aneurysms because thromboemboli are 
the most frequent complication associated with aneurysm coiling (L. Pierot et al., 2013).  
As experience developed, evidence came to light demonstrating crucial 
challenges presented to coiling EVT. First and foremost the unfavorable shape of the 
aneurysm made them very difficult to treat, particularly large neck aneurysms, fusiform 
aneurysms, large and giant aneurysms and aneurysms with unfavorable size relationship 
between aneurysms dome, neck and parent artery. Soon new technologies and 
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techniques developed in order to better address this issue, including balloon-assisted 
coiling (known as the remodeling technique), aneurysm coiling supported by stenting 
and more recently the introduction of flow diversion or disruption. Recanalization also 
became a great challenge to aneurysm coil embolization reducing its durability. Since 
aneurysms are due to plastic deformation of vessel wall and its underlying factors are 
not just operational at the sac but also around the neck region, recurrences following 
EVT are not unlikely. In 2009, a systematic review of forty-six studies including 8161 
coiled aneurysms was published reporting a recanalization rate of 20.8% and a 
performed retreatment rate of 10.3% (Ferns et al., 2009). Although recanalization and 
regrowth are often used interchangeably, recanalization means the opening of the 
previously embolized aneurysms. In recanalized cases, the aneurysm sac has the same 
size, but the coils have been displaced from the neck. Even in densely packed 
aneurysms, coils can only occupy about 30% of the sac volume, leaving the rest of the 
volume to be filled by cloth. Hemodynamic stress can then press the coil mass towards 
the dome leaving the neck region exposed and vulnerable to the blood flow once again. 
Regrowth, on the other hand, implies that the aneurysm size has become larger and the 
coil mass is no longer sufficient to occlude it  (Islak, 2013). ISAT trial results showed 
that only about 66% of coiled aneurysms achieve complete occlusion at the end of the 
treatment and those incompletely embolized convey a greater concern for retreatment 
(A. Molyneux et al., 2002; A. J. Molyneux et al., 2005). For over 10 years, packing 
coils as tightly as possible has been reported to be crucial in order to avoid 
recanalization. However, residual volume after coil embolization, which is a composite 
variable of packing density and aneurysm volume, has been demonstrated to be the most 
influential risk factor for recanalization (Sadato et al., 2016). The goal of embolization 
should not be established as a fixed value for packing density because the larger the 
aneurysm volume, the greater the packing density needs to be in order to minimize the 
residual volume and the risk of recanalization (Sadato et al., 2016). Surface modified 
coils have also been developed as an effort to reduce the recanalization rate, including 
polyglycolic-lactic acid coils and Hydrocoils (Microvention, Tustin, CA) but large 
multicenter series have shown that they were not more efficacious than bare platinum 
coils (L. Pierot et al., 2008; White et al., 2011; White et al., 2008). The clinical 
significance of aneurysm recanalization is still not entirely understood. Early rerupture 
of treated aneurysms occurs more frequently than delayed rerupture and has major 
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clinical consequences. The Cerebral Aneurysm Rerupture After Treatment (CARAT) 
study established the degree of aneurysm occlusion after the initial treatment as a strong 
predictor of the risk of subsequent rupture in patients presenting with subarachnoid 
hemorrhage (SAH), therefore justifying attempts to completely occlude aneurysms 
(Johnston et al., 2008). Anatomical follow-up with digital subtraction angiography 
(DSA) and magnetic resonance (MR) imaging became mandatory as surveillance for the 
risk of aneurysm recanalization (L. Pierot et al., 2006; L. Pierot, Portefaix, et al., 2012).     
 
Balloon-Assisted Coil Embolization (BACE) 
 Wide necked aneurysms or unfavorable anatomic conditions (e.g., access or 
parent vessel tortuosity or vessel angulation) can be technically challenging for 
conventional EVT of IA. Coils deployed without supporting devices may herniate from 
the aneurysmal sac into the parent artery, causing thromboembolic complications or 
vessel occlusion. The effort to overcome these difficulties has brought alternative 
strategies such as stent-assisted coil embolization (SACE) and balloon-assisted coil 
embolization (BACE; also known as remodeling technique). BACE, as it has been 
initially described by Moret, allows for optimal coil packing particularly in the 
aneurysm neck and fundus (Moret et al., 1997). A nondetachable balloon is temporarily 
inflated in front of the neck of the aneurysm during each coil placement (L. Pierot, 
Cognard, et al., 2012). In sidewall aneurysms, the balloon is simply placed in the parent 
vessel in front of the aneurysm neck. As for bifurcation aneurysms, a more complex 
approach is required and multiple options are available: using 2 balloons, a hyper-
compliant balloon, a round shaped balloon, or even using a double lumen balloon. 
When the procedure is over, the balloon is deflated and removed, and no extra-
aneurysmal device is left in place unless a stenting is subsequently performed (L. Pierot 
et al., 2013). Some retrospective, single center studies have reported an increase in 
mortality associated with BACE or a trend towards a higher thromboembolism 
complication rate (Sluzewski et al., 2006; van Rooij et al., 2006). The rates of 
thromboembolic events and intraoperative rupture were higher in the BACE group 
(9.8% and 4.0%, respectively) as compared with the coiling alone subgroup (2.2% and 
0.8%, respectively). However, these concerns could not be reproduced by several larger, 
more recent studies and literature reviews. In fact, two large multicenter prospective 
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series using BACE in both ruptured (Clinical and Anatomical Results in the Treatment 
of Ruptured Intracranial Aneurysms [CLARITY]) and unruptured (Analysis of 
Treatment by Endovascular approach of Non ruptured Aneurysms [ATENA]) 
aneurysms, re-evaluated the complication rates comparing BACE to coiling alone 
(Laurent Pierot et al., 2011; L. Pierot et al., 2009). In ruptured aneurysms the rate of 
thromboembolic events was similar in both groups (12.7% in the coiling group and 
11.3% in the BACE group) and a similar result was reported for the rate of 
intraoperative rupture (4.4% in both groups). The treatment morbidity was 3.9% in the 
coiling group and 2.5% in the BACE group, and treatment mortality 1.2% in the coiling 
group and 1.3% in the BACE group (Laurent Pierot et al., 2011). As for the unruptured 
aneurysms, ATENA showed that the rate of thromboembolic events was not higher in 
the BACE group as compared with coiling alone (5.4% versus 6.2%) with similar 
clinical outcome in both groups. The rate of intraoperative rupture was 3.2% in the 
BACE group and 2.2% in the coiling alone group, with clinical worsening (permanent 
deficit or death) in 0.6% in the coiling group and 1.4% in the BACE group. The 
treatment morbidity was 2.2% in the coiling group and 2.3% in the BACE group, 
whereas treatment mortality was 0.9% in the coiling group and 1.4% in the BACE 
group (L. Pierot et al., 2009).  
Table 2 - Ruptured Intracranial Aneurysms (CLARITY) 
  
 
  
Complications Coiling (%) BACE (%) 
Rate of Thromboembolic Events 12,7 11,3 
 
  
Rate of Intraoperative Rupture  4,4 4,4 
 
  
Morbidity 3,9 2,5 
 
  
Mortality 1,2 1,3 
 
Table 3 - Unruptured Intracranial Aneurysms (ATENA) 
  
 
  
Complications Coiling (%) BACE (%) 
Rate of Thromboembolic Events 6,2 5,4 
 
  
Rate of Intraoperative Rupture  2,2 3,2 
 
  
Morbidity 2,2 2,3 
 
  
Mortality 0,9 1,4 
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In a literature review, anatomic results were better with BACE (Shapiro et al., 
2008). Postoperatively, a total occlusion was observed in 73% of patients in the BACE 
group and in 49% of patients treated with coiling alone. At follow-up, similar results 
were observed. A total occlusion was observed in 72% of patients using BACE and in 
54% of patients treated with coiling alone. The Cerebral Aneurysm Rerupture after 
Treatment trial suggested that the rate of early repeat bleeding is directly related to the 
degree of postoperative aneurysm occlusion (Elijovich et al., 2008; Laurent Pierot et al., 
2011). Pierot published results showing a significantly higher adequate occlusion rate in 
the remodeling group compared to the conventional coil embolization group (94.9% 
versus 88.7%) despite the less favorable anatomic characteristics of aneurysms treated 
with BACE (Laurent Pierot et al., 2011). In the ATENA series (unruptured aneurysms 
only), postoperative anatomic results were not better in patients treated with BACE (L. 
Pierot et al., 2009).   
BACE, initially developed to better address the treatment of wide-necked 
aneurysms, has shown in recent series that in the setting of intraoperative rupture, 
balloon assistance was associated with a higher probability of unchanged or improved 
clinical outcome as compared with standard coiling (Santillan et al., 2012). In this 
retrospective analysis it is suggested that balloon assistance should not only be used as 
an enabler to coiling but could also be helpful in obtaining rapid hemostasis if 
intraprocedural aneurysmal rupture occurs resulting in better short-term outcomes. The 
balloon stays deflated across the neck of the aneurysm and is inflated only in case of 
intraoperative rupture. Perhaps because of this sentinel property, a steady increased over 
time use of the remodeling technique has been reported in the period between 2008 and 
2010. BACE was used in a similar percentage of cases independent of aneurysm 
characteristics (aneurysm status, location, size, and neck size), except dome-to-neck 
ratio (L. Pierot, Rajpal, et al., 2012).   
 
Stent-Assisted Coil Embolization  
Stent-assisted coil embolization (SACE) was introduced over ten years ago to 
overcome some limitations of standard coiling alone particularly concerning the 
treatment of some complex aneurysms, including those with low dome-to-neck ratios 
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and those with wide necks (Beller et al., 2016). Preventing coil prolapse and allowing 
higher packing density are benefits attributed to SACEs mechanical effects, but flow 
diversion may also contribute to potential hemodynamic effect. Stent struts can directly 
reduce flow velocity and also have a relevant role straightening the vessels-aneurysm 
complex (Kono et al., 2014). Initially conceived for the treatment of sidewall 
aneurysms, with gained experience and further technical refinement, bifurcation 
complex-shaped wide-neck aneurysms have successfully been treated with SACE 
(Piotin et al., 2014). The development of low-profile stents is a further interesting 
evolution that allows for the association of both BACE and SACE (Kadziolka et al., 
2013). Different stent-placement methods have allowed treatment of a subset of wide 
necked aneurysms not amenable to reconstruction with a single stent due to anatomical 
conformation. Y-stent reconstruction is an example of one of these methods, indicating 
that a second stent is advanced through the first stent interstices and into the 
contralateral branch vessel, enabling a variety of complex aneurysms to be treated with 
SACE safely and with satisfactory mid-term results (Spiotta et al., 2011).  
Risk of implant thrombosis is higher in SACE than with coiling alone since 
stents are implanted in the parent artery, bridging the aneurysm neck. Acute SAH is a 
hypercoagulable state in which the tendency for thrombosis is high and the insertion of 
an endovascular stent induces an even higher risk of parent vessel occlusion, thus 
making antiplatelet therapy during and after the procedure mandatory (L. Pierot et al., 
2013). Presently, in the setting of SAH, most operators are reluctant to use antiplatelet 
therapy because of the potential need for a ventriculostomy, the potential for infarction 
secondary to vasospasm, and the high likelihood of future invasive interventions (in 
which antiplatelet therapy may be anticipated as harmful). This is the main reason why 
stent placement is generally avoided in acutely ruptured aneurysms in favor of clip 
ligation or other endovascular techniques that do not mandate dual antiplatelet therapy 
(Bechan et al., 2015). Though this initially limited SACE to unruptured aneurysms, 
gaining experience during the past years has extended its use towards ruptured 
aneurysms (L. Pierot et al., 2013; Tahtinen et al., 2009). Intracranial stents are 
considered to be thrombogenic until they are covered by endothelium with reacquired 
normal intrinsic fibrinolytic activity. Stent deployment in unruptured intracranial 
aneurysms usually requires pre- and post-procedural treatment with clopidogrel and 
acetylsalicylic acid; however, these drugs are contraindicated in cases of acute SAH and 
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nonsecured aneurysm. Perioperative infusion of acetylsalicylic acid has been shown 
effective at reducing thromboembolic events rate without increasing the intraoperative 
bleeding rate, thus being advocated in the EVT of aneurysms, including during acute 
SAH (Tahtinen et al., 2009).      
The safety and efficacy of SACE as compared with standard coiling has been 
evaluated in few and mostly retrospective single-center series. Prospective, multicenter 
series performed and published are scarce and presently no prospective randomized 
clinical trials have been published comparing standard coiling with SACE.  
A recent observational study with prospectively collected data found that the 
symptomatic complication rate with early adverse events of SACE in patients with 
ruptured aneurysms was very high and 10 times higher (22% versus 2.2%)  than that in 
stent-assisted coiling of unruptured aneurysms (Bechan et al., 2015). Mortality was 
attributable mostly to early rebleed and in addition, ruptured aneurysms patients treated 
with SACE also underwent fatal hemorrhagic complications from extraventricular drain 
placement or even spontaneous remote intracranial hemorrhages. In ruptured aneurysms 
SACE was associated with increased morbidity-mortality rate (13%) prompting 
recommendation to consider this option only when less risky ones had been excluded 
(Bechan et al., 2015).  
A systematic review and meta-analysis has been conducted precisely to compare 
SACE with coiling-only for intracranial aneurysms in terms of immediate occlusion, 
progressive thrombosis, recurrence, and complication profile (Phan et al., 2016). There 
were 14 observational studies involving 2698 SACE patients and 29388 coiling-only 
patients harboring ruptured and unruptured aneurysms. 12 studies reported immediate 
occlusion rates with no significant statistical difference in pooled immediate occlusion 
rates for the SACE group (57.7%) and for the coiling-only group (48.7%). For 
progressive thrombosis (increases in packing density on follow up) six studies reported 
a higher pooled progressive thrombosis rate in the SACE group (29.9%) in comparison 
with the coiling-only (17.5%). 10 studies reported recurrence rates showing a 
significantly lower likelihood of aneurysm recurrence in the SACE group (12.7%) than 
in the coiling-only group (27.9%). Stents divert flow away from the aneurysm sac, thus 
favoring stasis and thrombosis within the aneurysm and they can also provide a scaffold 
for endothelialization and growth of fibroelastic tissue at the aneurysm neck level. 
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Stented-coiling cases were frequently biased towards aneurysms with particularly wide 
necks (>4 mm) and low dome-to-neck ratios, which are known predictors of aneurysm 
recurrence, reinforcing SACEs aneurysm recurrence rates results. The pooled rate of all 
complications was similar in both groups (12.2% versus 12.0%) showing no significant 
difference. Pooled rate of permanent complications also had no significant statistical 
difference between groups, although it was higher in the SACE group (4.1% versus 
3.5%). Thrombotic complications rate was analogous in both SACE and coiling-only 
groups (4.5% versus 4.1% respectively). Pooled mortality rates were significantly 
higher in SACE group (1.4%) compared to the coiling-only group (0.2%). Procedure-
induced mortality occurred in 4.6% (10 of 216) of stent-assisted coiling versus 1.2% (13 
of 1109) of coiling without stents. However, almost all studies had no significant 
increase in mortality for stented patients compared to coiling-only. This pooled 
increased risk of death might be explained not only by the significantly larger aneurysm 
sizes in the stented patients compared to the non-stented patients, but also by the type of 
stents used (balloon-expandable stents were used early in the study while self-
expandable stents were not yet available). Despite stented aneurysms often having more 
difficult morphologies, this technique was associated with lower rates of aneurysm 
recurrence, higher rates of progressive thrombosis and similar complication outcomes 
compared to coiling-only. However, SACE was associated with a higher mortality rate 
(Phan et al., 2016). 
Another systematic review and meta-analysis sought out to review the literature 
concerning SACE in comparison with coiling without stents in terms of safety and 
effectiveness profiles (Feng et al., 2016). 16 studies clearly reporting patient outcomes 
were included with a total of 4294 aneurysms. 1466 aneurysms were treated with SACE 
and 2828 aneurysms were addressed with conventional coiling. The mean proportion of 
patients with ruptured aneurysms included in the stent-assisted group was 13.14%, 
significantly less than in the nonstent group, which was 33.71%. Immediate occlusion 
rates showed no statistical significant differences between the two groups. (53.18% vs 
55.59%). However, 2917 patients were subsequently analysed for follow up 
angiographic occlusion rate revealing a higher angiographic occlusion rate in the SACE 
group relative to the nonstent group (60.58% vs 36.05% respectively). Better results 
were also reported in the SACE group than in the nonstent group for progressive 
thrombosis rate (44.09% vs 22.68% respectively) and lower recurrence rate was 
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reported (13.31% vs 29.13%). Overall complication rates showed no statistically 
significant difference between the two groups (11.85% versus 8.00%). 12 retrospective 
studies also conveyed no significant statistical difference concerning hemorrhage stroke 
rate in the perioperative period (2.46% versus 2.72%) but instead revealed a higher 
incidence of ischemic stroke in the SACE group than the nonstent group (4.68% versus 
1.99%) (Feng et al., 2016).  
The question remains of whether stent-assisted techniques should be 
systematically used for all aneurysms regardless of their morphology. Randomized 
controlled trials are required to answer this question (Phan et al., 2016).  
 
 
Flow-Diversion 
Flow Diverter Devices (FDDs) represent a recent and important effort emerging 
from endovascular treatment technology aimed at obtaining higher occlusion rates, 
decreasing recurrence and recanalization of difficult-to-treat  intracranial aneurysms 
(IA) - wide-necked, fusiform, giant aneurysms or those with complex morphology - 
comparatively to more conventional endovascular techniques (F. Briganti et al., 2016; 
Francesco Briganti et al., 2014).  
Endoluminal approach with FDDs allows reconstructive treatment and vascular 
remodeling for these challenging aneurysms. These new devices consist of highly dense 
mesh stents, placed in the parent artery at the level of the neck, reducing hemodynamic 
exchange with the aneurysm and thus promoting thrombosis within the aneurysm sac 
(Giacomini et al., 2015). The device also provides scaffolding for strong neointimal 
overgrowth, remodeling the parent artery and curing the neck (Giacomini et al., 2015) 
while preserving patency of adjacent small vessels (Francesco Briganti et al., 2014). 
The result seems to be a more anatomically definitive and durable treatment of the 
aneurysm (Becske et al., 2013). Determining the type of endovascular procedure with 
FDDs and its indications remains a challenging task. A great deal of variables need to 
be taken into account as influencing factors for occlusion, such as aneurysm size, 
location and morphology, parent vessel geometry, blood coagulation parameters, 
previously regular stent use as well as resulting flow changes (Giacomini et al., 2015). 
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Flow diversion can be combined with coil embolization, further expanding the treatment 
options (Amuluru et al., 2016). Despite the high occlusion rate obtained by FDDs 
techniques, the associated morbidity and mortality should not be neglected and in fact, 
as the popularity of such techniques grows higher, various complications inevitably 
appear, such as spontaneous rupture, intraparenchymal hemorrhage (IPH), ischemic 
stroke, parent artery aneurysm stenosis, and neurological complications (Ye et al., 
2016). To date, the safety issues and efficiency of FDDs have not been fully evaluated 
(Zhou et al., 2016). 
 
Flow-Diversion Devices: 
Silk 
In 2007, the Silk flow-diverting stent (SFD; Balt Extrusion, Montmorency, 
France) became the first FDD ever to enter clinical use for intracranial circulation 
(Amuluru et al., 2016). Silk FDD consists of 48 braided Nitinol strands offering a high-
coverage mesh once expanded and is available in different diameters (2–5 mm) and 
lengths (15–40 mm) for the treatment of aneurysms of different sizes and in different 
locations (Maimon et al., 2012).  
A systematic review of the published literature concerning SFD in the treatment 
of intracranial aneurysms, including results from eight studies, was presented by S.B. 
Murthy (Santosh B. Murthy et al., 2014). This review examined a total of 285 patients 
with 317 intracranial aneurysms, of which 87% (n=275, 95% CI: 83-90.5%) were 
present in the anterior circulation and the remaining 13% (n=42, 95% CI: 9.5-16.9%) 
were found in the posterior circulation. In terms of size, 17.7% (n=52, 95% CI: 13.3-
22.1%) of aneurysms were classified as giant, 44.4% (n=130, 95% CI: 38.7-50.1%) of 
aneurysms were classified as large (10-24 mm) and 37.9% (n=11, 95% CI: 32.4-43.5%) 
were classified as small. The cumulative aneurysm occlusion rate (AOR) was 81.8% 
(95% CI: 77.1-86.5%) with complete occlusion in 216 aneurysms from a total of 264 
aneurysms with available angiographic follow-up information at 12 months. 
Periprocedural complications rate was 12.5% (n=36, 95% CI: 8.7-16.3%), while the 
delayed complication rate was 9.9% (n=28, 95% CI: 6.4-13.4%). Ischemic (including 
both stroke and transient ischemic attack – TIA) and parent artery occlusion (PAO) 
were the most common complications, each occurring in a total of 29 (10.2%) patients. 
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The overall observed mortality rate was 4.9% (n=14, 95% CI: 2.4-7.4%) (Santosh B. 
Murthy et al., 2014). 
The SFD has undergone multiple revisions since its first clinical implementation 
in 2008.  As a result, a second generation of SFD has been developed, the Silk+ stent 
(Amuluru et al., 2016). According to B. Lubicz, the Silk stent has been significantly 
improved with the release of the Silk+ stent, which has flared ends, a higher radial 
force, and a higher radio-opacity (Lubicz et al., 2015). In a series of 58 patients (32 
treated with Silk stent and 26 treated with the Silk+ stent) the second generation device 
provided better stent tolerance at the acute phase of endovascular treatment and no 
clinical complication was experienced both during periprocedural phase and follow-up 
(Lubicz et al., 2015).   
 
Pipeline Embolization Device (PED) 
In 2008, the Pipeline Embolization Device (PED; ev3/Covidien, Irvine, CA) was 
launched. PED is an endoluminal, self-expanding, bimetallic braided device, comprised 
of platinum (25%) and cobalt-nickel alloy (75%) (S. B. Murthy et al., 2016).  
Three major studies have been published establishing safety profile and 
aneurysm occlusion rate (AOR) of PED: (1) Pipeline for Uncoilable or Failed 
Aneurysms: Results from a Multicenter Clinical Trial (PUFS) (Becske et al., 2013); (2) 
Pipeline Embolization Device for the Treatment of Aneurysms (PITA) (Nelson et al., 
2011); (3) International Retrospective Study of Pipeline Embolization Device 
(IntrePED) (Kallmes et al., 2015). These important trials concluded that Pipeline 
Embolization Devices (PEDs) were associated with high aneurysm occlusion rates 
(AOR) and rates of adverse events comparable to those of more conventional 
techniques.  
The IntrePED study (Kallmes et al., 2015) retrospectively evaluated 793 
consecutive patients with 906 intracranial aneurysms (91% unruptured) treated with the 
Pipeline Embolization Device in 17 centers worldwide. Most (838 aneurysms) were 
located in the anterior circulation (92.5%), while 59 aneurysms were in the posterior 
circulation (6.5%) – no combined information on location/size was available for 9 
aneurysms. 66 aneurysms (7.3%) were classified as giant, 357 aneurysms (39.8%) were 
large and 473 aneurysms (52.8%) were small. Median follow-up was 19.3 months with 
706 (89%) of patients having follow-up of >12 months. Intraparenchymal hemorrhage 
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(2.4%) and ischemic stroke (4.7%) were the most common complications. The overall 
mortality rate was 3.8% with high heterogeneity among the groups. Patients with 
posterior circulation aneurysms had higher rates of neurologic mortality (10.9%) as well 
as patient with giant aneurysms (9.6%) or patients who presented with ruptured 
aneurysms (10.5%) (Kallmes et al., 2015). A recent prospective study from the same 
author, included 191 patients with 207 aneurysms treated with PED, established a 
complete occlusion  rate of 75% at 8 months angiographic follow-up (Kallmes et al., 
2016). 
New flow diverts have been developed in order to optimize the effect on flow 
reduction within the aneurysmal sac while keeping the side branches (perforators) 
patent and thus reducing the need for additional device implementation. 
 
Surpass  
 The surpass flow diverter (Stryker Neurovascular, Fremont, California) currently 
available in Europe, is composed of cobalt-chromium with a low porosity (metal surface 
area coverage of 30%); a high mesh density (20-32 pores/mm) and a self-expanding 
single-layer braided, tubular structure (Wakhloo et al., 2015). It comes in various 
diameters and lengths but its design allows the porosity to remain 70% across all 
Surpass sizes (Fargen et al., 2015). A prospective multicenter study, with 165 patients 
treated with Surpass for 190 intracranial aneurysms of the anterior and posterior 
circulation, concluded a clinical safety profile for these diverters comparable with that 
of stent-assisted coil embolization as well as a high rate of intracranial aneurysm 
occlusion (75%) (Wakhloo et al., 2015).  
 
FRED (Flow-Redirection Endoluminal Device) 
 FRED (Microvention, Inc., Tustin CA, USA) consists of a braided self-
expandable closed-cell dual-layer stent (known as “stent within a stent”) with a low-
porosity inner mesh of higher pore attenuation (48 nitinol wires) and an outer stent with 
high porosity (16 nitinol wires (Yoshimura, 2016). 
 A single-center observational study has been reported to assess the clinical 
safety and efficacy of FRED (Mohlenbruch et al., 2015). This study included 29 patients 
with 34 aneurysms elected to be treated by endovascular intervention fulfilling the 
following registration criteria after informed consent: aneurysm fondus-to-neck ratio <2 
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or neck diameter >4 mm, fusiform, dissecting, or giant aneurysms. The efficacy end 
point was O’Kelly Marotta grading scale D (complete angiographic occlusion) 
immediately after procedure and at follow-up after 3 and 6 months. Primary clinical 
safety end point was established as the absence of death, absence of major or minor 
stroke, and absence of transient ischemic attack. The device was successfully placed in 
all patients and the primary end point of safety was reached in 26/29 (89%) of patients; 
in the remaining 3 patients, 1 disabling ischemic stroke and 2 minor strokes with 
complete recovery at follow-up were observed. Angiographic (DSA and MRA) and 
clinical follow-up at 3 months were available for all patients (100%) while the 6 months 
follow-up (MRA) was performed in 25/29 patients (86%), reaching complete occlusion 
in 19/34 (56%) and 22/30 (73%), respectively. Deployment of the FRED flow-diverter 
stent was concluded to be safe and effective for the management of difficult-to-treat or 
otherwise untreatable intracranial aneurysms. 
 
Flow-Disruption Devices 
Woven Endobridge (WEB) 
Flow-Disruption Devices are intra-saccular braided-wire embolization devices 
designed to disrupt blood flow at the level of aneurysm neck–parent artery interface. 
Two models are available in the market: the Woven Endobridge (WEB II) device 
(Sequent Medical, Inc., Aliso Viejo, CA, USA) and LUNA Aneurysm Embolization 
System (AES) (NFocus Neuromedical, Palo Alto, California) (Klisch et al., 2011). 
 A recent systematic review of literature has been conducted by Ivo S. Muskens 
aiming at evaluating clinical outcomes of intracranial aneurysms (especially bifurcation 
and wide-neck aneurysms) treated with a WEB device (Muskens et al., 2016). This 
review included 19 papers (prospective/retrospective studies; multicenter/case-series) 
reporting on clinical outcome with WEB devices in 687 patients with 718 aneurysms 
(both ruptured and unruptured). The two most significant prospective multicenter 
studies in this review (WEBCAST and the French Observatory Trial) presented rates of 
complete aneurysm occlusion with the WEB device of 56%-52% respectively. 
Adequate occlusion is, however, often regarded as complete occlusion or a small neck 
remnant, which would increase the rate to 85%-79% respectively with this standard. No 
significant difference was found between ruptured and unruptured aneurysms rates in 
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this review, but the authors state that no adequate comparison can be made due to great 
variability in patient characteristics and few studies reporting the use of WEB device for 
ruptured aneurysms (Muskens et al., 2016). Both the WEBCAST and the French 
Observatory Trial had limited follow-up (6 and 12 months respectively) as well as 
incomplete follow-up (85% and 94% respectively) (Muskens et al., 2016). Procedural 
aneurysm rupture was reported associated with WEB device placement in 10 patients, 
while thromboembolic events were reported more frequently with 71 patients (10.3% of 
all cases) and infarction in 8 cases (1.2% of all cases). Rebleeds were reported in just 5 
patients in two studies with mean follow-up of 3.3 and 14.4 months (Muskens et al., 
2016). The WEB device is potentially associated with a considerable learning curve 
making a practice model a necessity (Muskens et al., 2016).  
 S. Asnafi published the most recent systematic review and meta-analysis of 
existing literature on the Woven Endobridge device in the treatment of intracranial 
aneurysms (Asnafi et al., 2016). Fifteen uncontrolled series with 565 patients harboring 
588 aneurysms (of which 127 ruptured) were included. Initial results presented a 
complete and adequate (complete occlusion or a small neck remnant) occlusion rates of 
27% and 59% respectively that increased to 39% and 85% rates at a mean follow up 
time of 7 months. Again, no significant differences were found in midterm (>3 months) 
adequate occlusion rates between ruptured and unruptured aneurysms (85% and 84% 
respectively), as well as, no relevant differences in perioperative morbidity and 
mortality rates (4% and 1% respectively) (Asnafi et al., 2016). 
 Literature on the Woven Endobridge device seems to present promising results 
regarding safety profile and adequate occlusion rates, especially if taken into account 
the complexity of aneurysms treated (Asnafi et al., 2016). Further studies are needed to 
better assess complication rate and long term efficacy of the Woven Endobridge device 
in treating wide-neck and wide-neck bifurcation aneurysms (Caroff et al., 2014).  
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Table 4 - Summary of Relevant Technical Prognostic Factors in EVT of ICA 
Factor 
Analysed complication / 
Outcome measurement 
Favourable / 
Unfavourable / 
Controversial / 
Neutral 
Class of 
evidence 
Or 
Suggested 
Power 
Recommendation Commentary Reference 
Hyper-early 
treatment (<12h 
after SAH) 
N/A Unfavourable 2b Avoid? Single center study 
(Consoli et al., 
2013) 
Treatment within 
24h after SAH 
- Degree of disability or 
dependence in daily 
activities (modified 
Rankin Scale) 
Favourable 2b Implement 
Single center 
prospective study 
(Phillips et al., 
2011) 
Early Treatment (12 
to 72h after SAH) 
N/A 
 
Favourable 2b Implement Single center study 
(Anxionnat et al., 
2015) 
Consoli et al., 
2013) 
High vs Low Volume 
Centers 
- Symptomatic 
vasospasm 
- 12-month follow up 
Unfavourable 2b 
- Early resuscitation and 
stabilization followed by 
safe transfer rather than 
a hyperacute transfer 
paradigm 
Retrospective cohort 
study 
Nuno et al., 2012; 
Wilson et al., 
2015 
Coiling 
- Thromboembolic 
complications 
-Intraoperative rupture 
- Neutral 2b  
Large multicenter 
prospective series 
Cognard et al. 
Coiling (Hydrogel-
coated coils) 
- Thromboembolic 
events 
-  (angiographic and 
clinical outcomes at 18 
month follow-up) 
- Neutral 
 
2b  
Large multicenter 
prospective series 
White et al., 2011 
 
Coiling (Matrix coils) Anatomic results  Unfavourable 2b  
Large multicenter 
prospective series 
 
Laurent Pierot et 
al., 2008 
BACE 
- Thromboembolic 
events 
–Intraoperative rupture 
Unfavourable 2b Avoid? Single center studies 
Sluzewski et al., 
2006; van Rooij et 
al., 2006 
BACE 
 
- Thromboembolic 
events 
- Intraoperative rupture 
Neutral 2b  
Large multicenter 
prospective series 
CLARITY 
BACE 
 
- Thromboembolic 
events and 
intraoperative rupture 
Neutral 2b  
Large multicenter 
prospective series 
ATENA 
BACE - Anatomic results Favourable  Consider using  
Shapiro et al., 
2008 
BACE 
 
 
- Hemostasis if 
intraprocedural 
aneurysmal rupture 
Favourable 2b 
Consider using (as a 
safety measure) 
 
Santillan et al., 
2012 
Degree of 
postoperative 
aneurysm occlusion 
- Early repeat bleeding Favourable  
To increase the degree 
of aneurysm occlusion 
 
Elijovich et al., 
2008; Laurent 
Pierot et al., 2011 
 
SACE 
- Thromboembolic 
events 
- Intraoperative rupture 
Favourable 2b 
Consider for ruptured 
wide-necked intracranial 
aneurysms that are 
difficult to treat with 
balloon-assisted 
embolization 
Multicenter 
retrospective series 
Tahtinen et al., 
2009 
SACE 
- Thromboembolic 
events and early 
reebleeds 
Controversial 
(complication rate of 
SACE with early 
adverse events in 
ruptured ICA was 10 
times higher than that 
in unruptured ICA) 
2b 
Ruptured ICA: avoid in 
favor of other surgical or 
endovascular 
treatments without the 
need for antiplatelet 
medication  
Large multicenter 
prospective series 
Bechan et al., 
2015 
SACE 
- Thromboembolic 
events 
- Recurrence rate 
Favourable 2a 
Further randomized 
controlled trials are 
required 
Meta-analysis Phan et al., 2016 
SACE 
- Thromboembolic 
events and  
- Recurrence rate 
Favourable 2a 
Multicenter, randomized 
controlled studies are 
necessary to confirm 
Systematic Review and 
Meta-analysis 
Feng et al., 2016 
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these findings 
Silk (Flow Diversion 
Device) 
- Thromboembolic 
events 
- Parent artery occlusion 
- Intraoperative rupture 
Higher incidence of 
complications 
relatively to PED 
2a 
Further randomized 
controlled trials are 
required 
Systematic Review 
Santosh B. 
Murthy et al., 
2014 
Silk (Flow Diversion 
Device) 
- Thromboembolic 
events  
- Intraoperative rupture 
Favourable (for 
complex ICA – Silk + 
Stent appears safer 
than first generation 
stents 
1b  
Single center 
retrospective series 
Lubicz et al., 2015 
Pipeline 
Embolization Device 
(Flow Diversion 
Device) 
- Thromboembolic 
events and 
intraoperative rupture 
- Follow up at 180 days 
Favourable 
(technically feasible 
and can be achieved 
with an acceptable 
level of periprocedural 
risk) 
2b  
Prospective multicenter 
trial 
(The optimal application 
of these devices will 
continue to be defined 
as clinical experience 
evolves) 
Nelson et al., 
2011 (PITA) 
Pipeline 
Embolization Device 
(Flow Diversion 
Device) 
- Thromboembolic 
events  
- Intraoperative rupture 
- Follow up at 30 and 
180 days after PED 
placement 
Favourable (PED is 
safe and effective for 
the target population 
of large and giant 
wide-necked anterior 
cerebral circulation 
aneurysms) 
2b 
Continued study of PED 
to refine therapy and 
further understand 
certain complications 
that occur infrequently 
is warranted 
Multicenter prospective 
interventional single arm 
trial  
Becske et al., 
2013 (PUFS)  
Pipeline 
Embolization Device 
(Flow Diversion 
Device) 
- Thromboembolic 
events  
- Intraoperative rupture 
Favourable (The 
complication rates 
with PED are 
comparable with 
those of other 
endovascular 
treatment options 
such as SACE) 
2b 
- PED is associated with 
the lowest complication 
rates when used to treat 
small aneurysms of the 
anterior circulation 
- Patients with posterior 
circulation aneurysms 
and giant aneurysms are 
at higher risk of 
thromboembolic 
complications 
Multicenter 
retrospective study 
Kallmes et al., 
2015 (IntrePED) 
Surpass 
(Flow Diversion 
Device) 
- Thromboembolic 
events  
- Intraoperative rupture 
Favorable (acceptable 
safety profile 
compared with other 
FD technology and 
stent-assisted coil 
embolization) 
2b 
- The observed 
progressive occlusion 
requires long-term 
follow-up studies 
- Prospective 
multicenter 
nonrandomized, single 
arm study 
Wakhloo et al., 
2015 
Flow-Redirection 
Endoluminal Device 
(Flow Diversion 
Device) 
- transient or permanent 
neurologic deficit or 
death 
- Thromboembolic 
events  
- Intraoperative rupture 
Favourable 2b 
- Long-term durability 
and safety still remain to 
be proved by larger 
series and after 
prolonged followup 
- Reasonable, safe, and 
effective to use 
Single-center 
prospective 
observational study 
Mohlenbruch et 
al., 2015 
Woven Endobridge 
(Flow-Disruption 
Devices) 
- Thromboembolic 
events  
- Intraoperative rupture 
- Controversial (great 
heterogeneity in the 
studies) 
2a 
- WEB device has been 
investigated mainly in 
unruptured aneurysms 
with a wide neck, which 
make results difficult to 
extrapolate to other 
aneurysms 
- Long-term results 
remain unknown 
Systematic review 
Muskens et al., 
2016 
 
Meta-analysis 
 A recent meta-analysis included a total of 48 randomized, double-blind, and 
sham-controlled trials reporting 2508 patients with 2826 ruptured and unruptured 
aneurysms treated by FDD, documenting aneurysm occlusion, morbidity and mortality 
rates (Ye et al., 2016). At a mean follow-up interval of 6.3 months, this meta-analysis 
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found an aneurysm occlusion rate of 77.9 % as well as a neurological morbidity and 
mortality rates of 9.8 % and 3.8 % respectively (Ye et al., 2016). The spontaneous 
rupture rate after FDD therapy was found to be significantly higher in giant aneurysms 
than in small/large aneurysms (7.5 % vs 1.3 %) and also higher in ruptured aneurysms 
than in unruptured ones (3.5 % vs 1.7 %) (Ye et al., 2016). Intraparenchymal 
hemorrhage (IPH) is another potentially fatal complication after FDD treatment, often 
resulting in permanent neurological deficits, which appears to have a higher rate in giant 
aneurysms (Ye et al., 2016). Ischemic stroke is the most common postoperative 
complication after FDD and it rates higher in aneurysms of the posterior circulation (10 
% vs 4.9 %) and in giant aneurysms in comparison to small or large ones (9.5 % vs 5 %) 
(Ye et al., 2016).  
 
FDD: Complication stratified by aneurysm size (Ye et al., 2016) 
 
  
FDD: Complications stratified by aneurysm location (Ye et al., 2016)  
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FDD: Complications stratified by aneurysm condition (Ye et al., 2016) 
 
 
 
Discussion and Conclusion 
  
IAs management varies substantially and treatment decisions should primarily 
be based on aneurysm related factors, clinical status of the patient, and technical 
endovascular considerations. 
For asymptomatic UIAs the best management is still uncertain. A precise 
assessment of multiple significant elements such as age and life expectancy of the 
patient, estimated risk of aneurysm rupture, risk of complications attributed to the 
preventive treatment, and the level of anxiety caused by the awareness of having an 
aneurysm are critical when defining therapeutic management. Several models have been 
developed to help predict the risk of rupture of incidental intracranial aneurysms. 
Despite considering both patient related predictors and aneurysm related predictors, the 
PHASES score has some limitations such as subgroup underrepresentation, limited 
long-term follow up and not considering the inherent risk of the intervention itself.  
Alternative models like UIATS (Unruptured Intracranial Aneurysm Treatment Score) 
encompass variables like young age or life expectancy, coexistent modifiable or 
nonmodifiable risk factors, coexistent morbidities, morphologic UIA features and 
relevance of clinical symptoms related to UIAs. However, its applicability is not as 
simple and the “population” of specialists used to elaborate this score is arguably 
representative of the general “community of UIA experts”. 
Ruptured
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Management of ruptured IA requires a multidisciplinary team of 
neuroradiologists, neurosurgeons and neurology intensive care physicians. Aneurysmal 
SAH clinical outcome is predicted primarily by neurological condition of the 
patient on admission, age, and the amount of extravasated blood seen on CT scans.  
Scales (including Fisher Scale, the Hunt and Hess Scale, the Glasgow Coma Score 
(GCS), and the World Federation of Neurological Surgeons (WFNS) Scale) have been 
projected to provide prognostic information regarding outcome. The Prognosis on 
Admission of Aneurysmal Subarachnoid Haemorrhage (PAASH) scale, grounded solely 
on the GDS, showed good prognostic value for patient outcome and an even better 
gradual increase in the proportionate distribution of patients with poor outcome per each 
increasing PAASH grade than the WFNS scale (van Heuven et al., 2008). 
Recurrent hemorrhage can follow at any time after the initial SAH in patients 
with both good and poor clinical grades, but the incidence of a recurrent hemorrhage is 
highest within 24 hours of subarachnoid hemorrhage (SAH) (Park et al., 2015). So it 
might seem reasonable to suggest that an even earlier treatment of the aneurysm 
would result in a better prognosis. But this would imply other complications, such 
as a greater risk of periprocedural unfavorable events, an increased need for 
retreatment and an increase in the number of patients transferred to different 
hospitals. Few data are available with reference to the effects of the EVT timing on 
clinical outcome. Hyper-early timing (<12 hours) for the neuro-interventional procedure 
doesn’t seem to be related with good clinical outcome, quite the opposite it appeared to 
show an inverse correlation with a good clinical outcome (Consoli et al., 2013). In 
another study published in 2011, two groups of patients treated before (ultra-early 
treatment) and after (early treatment) 24 hours, presented results showing better 
outcome at six months in the ultra-early approach group (within 24 hours) (Phillips et 
al., 2011). Lack of consensus on this issue is still a major concern. Guidelines propose 
aneurysm occlusion should be done promptly, within 72 hours and if possible 48 hours.  
Treatment should always be done as early as possible. However, if the patient is 
admitted more than 72 hours after hemorrhagic event and is considered to have a low 
risk for rebleed, treatment can be withheld if not for more than 10 days (Anxionnat et 
al., 2015; Matias-Guiu et al., 2013; Oudshoorn et al., 2014). 
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Low-volume hospitals should consider transferring patients with SAH to higher 
volume centers with specialized services, but there is currently a wide variance in 
transfer practices between institutions owing to the uncertainty related to optimal time 
frame for transfer and to the absence of specific recommendations to guide the process. 
Complications derived from delayed transfer have to be weighed against a hasty transfer 
process. Early resuscitation and stabilization followed by safe transfer rather than a 
hyperacute transfer paradigm should be the preferred protocol; however, transfer time 
should be minimized as much as possible with a goal of less than 8 hours, so that time 
to definitive treatment is not delayed (Wilson et al., 2015). 
The International Subarachnoid Aneurysm Trial (ISAT) demonstrated improved 
one-year clinical outcomes for patients with ruptured intracranial aneurysms treated 
with endovascular coiling compared to surgical clipping (A. Molyneux et al., 2002). 
Two large, prospective, multicenter series reviewed the two most frequent aneurysm 
coiling complications (thromboembolic complications and intraoperative rupture), and a 
good safety profile was found for both ruptured and unruptured aneurysms (Cognard et 
al., 2011; Laurent Pierot et al., 2008). Avoiding recanalization and approaching 
aneurysms with unfavorable characteristics were still presented as great challenges for 
coiling EVT and soon new technologies and techniques developed in order to address 
these limitations. 
BACE allows for optimal coil packing, particularly in the aneurysm neck and 
fundus (Moret et al., 1997). Despite initial concerns about safety profile, two large 
multicenter prospective series (CLARITY and ATENA) evaluated the complication 
rates comparing BACE to coiling alone (Laurent Pierot et al., 2011; L. Pierot et al., 
2009). In ruptured aneurysms the rate of thromboembolic events was similar for both 
groups and an analogous conclusion was found for the rate of intraoperative rupture. 
Treatment related morbidity was lower in the BACE group and mortality was similar 
for both groups (Laurent Pierot et al., 2011). As for unruptured aneurysms, 
thromboembolic events had a lower prevalence in the BACE group as compared with 
coiling alone and intraoperative rupture rate was slightly higher in the BACE group as 
compared to the coiling alone group. Safety of both techniques seems to be similar 
despite the fact that aneurysm characteristics treated with standard coiling are quite 
different from those treated with remodeling technique.  Also, a higher anatomic 
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efficacy is achieved with remodeling technique leading the authors to propose a wide 
use of remodeling technique (L. Pierot, Cognard, et al., 2012). 
Stent-assisted coil embolization (SACE) was introduced over ten years ago to 
overcome some limitations of standard coiling alone when applied to the treatment of 
complex aneurysms (Beller et al., 2016). Risk of implant thrombosis is higher in SACE 
than with coiling alone since stents are implanted in the parent artery, bridging the 
aneurysm neck. Antiplatelet therapy during and after the procedure is mandatory (L. 
Pierot et al., 2013). This is why stent placement may generally be avoided in acutely 
ruptured aneurysms in favor of other endovascular techniques that do not mandate dual 
antiplatelet therapy (Bechan et al., 2015). Safety and efficacy SACE profile as 
compared with standard coiling has been evaluated in few and mostly retrospective 
single-center series. In ruptured aneurysms SACE was linked with an increased 
morbidity-mortality rate and recommendations were made to consider this option only 
when less risky ones had been excluded (Bechan et al., 2015). A systematic review and 
meta-analysis compare SACE with coiling-only. Pooled immediate occlusion rates 
showed no significant statistical difference between both techniques while increases in 
packing density on follow up (pooled progressive thrombosis rate) were substantially 
higher with SACE. A significantly lower likelihood of aneurysm recurrence was 
associated with the SACE technique despite a bias towards cases with wide necked (>4 
mm) and low dome-to-neck ratio aneurysms. The question remains of whether stent-
assisted techniques should be systematically used for all aneurysms regardless of their 
morphology. Randomized controlled trials are required to answer this question (Phan et 
al., 2016).  
Even though safety and efficacy of intrasaccular detachable coil embolization 
are fairly well documented, the rate of aneurysmal total occlusion remains suboptimal 
and coil compaction achieved frequently result in post treatment recanalization and 
recurrence.  
Flow Diverter Devices (FDDs), highly dense mesh stents, are designed to further 
expand EVTs range and efficacy. The objective of getting a higher occlusion rates while 
decreasing recurrence and recanalization of difficult-to-treat intracranial aneurysms is 
attempted by reconstructive treatment and vascular remodeling (IA) (F. Briganti et al., 
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2016; Francesco Briganti et al., 2014). Knowing which type of FDD to use and its 
precise indications remains, however, a controversial issue (Giacomini et al., 2015). 
A systematic review of the published literature on SFDs applied primarily to 
giant or large aneurysms (63.1%) predominantly from the anterior circulation found a 
high cumulative aneurysm occlusion rate (AOR). The most common complications 
registered with this technique were ischemic events and parent artery occlusion 
(Santosh B. Murthy et al., 2014). More recently, an improved second generation of SFD 
has been developed, the Silk+ stent, with promising results. However, further evaluation 
of this device is needed at multiple centers with adequately trained operators (Binning et 
al., 2011; Lubicz et al., 2015). 
A greater amount of published data is available with regard to Pipeline 
Embolization Device (PED; ev3/Covidien, Irvine, CA). Major trials conducted have 
concluded that PED was associated with a high aneurysm occlusion rate (AOR) and a 
rate of adverse events comparable to those of more conventional techniques (Kallmes et 
al., 2015). Moreover PED treatment elicited a very high rate (93%) of complete 
angiographic occlusion at 6 months in a population of the most challenging anatomic 
subtypes of cerebral aneurysms (Nelson et al., 2011). 
A prospective multicenter study on the Surpass Flow Diverter (Stryker 
Neurovascular, Fremont, California) concluded a clinical safety profile comparable to 
stent-assisted coil embolization as well as a high rate of intracranial aneurysm 
occlusion.  Additionally, long-term follow-up studies are required due to the observed 
progressive occlusion (Wakhloo et al., 2015).  
FRED (Microvention, Inc., Tustin CA, USA), a 2-layer structure, consisting of 
high-porosity outer and low-porosity inner layers, is easy to guide or insert in or into a 
catheter, and wall apposition is favorable, facilitating recapture during insertion. 
Although showing promising results, most prospective studies on FREDs safety profile 
and efficacy include a very limited number of patients, short follow-up periods and lack 
randomized comparisons with other potentially efficacious therapies. Long-term 
durability and safety still remain to be proved by larger series and after prolonged 
follow-up (Matsumaru et al., 2016; Mohlenbruch et al., 2015). 
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Despite showing excellent occlusion rates, even in large and giant aneurysms, 
flow diverters have had limited clinical utility in rupture aneurysms (due to the 
requirement for concomitant dual antiplatelet therapy and because immediate aneurysm 
occlusion usually does not occur) and in bifurcation aneurysms owing to the inherent 
design limitations (Kwon et al., 2011).  In this context, intra-saccular braided-wire 
embolization devices were designed to disrupt blood flow at the level of aneurysm 
neck–parent artery interface (WEB and LUNA)(Kwon et al., 2011). 
A recent systematic review of literature has been conducted to assess clinical 
outcomes of intracranial aneurysms treated with a WEB device. Initial results presented 
a complete and adequate (complete occlusion or a small neck remnant) occlusion rates 
of 27% and 59% respectively, that increased significantly at a mean follow up time of 7 
months. No significant differences were found in midterm (>3 months) adequate 
occlusion rates between ruptured and unruptured aneurysms, as well as no relevant 
differences in perioperative morbidity and mortality rates (Asnafi et al., 2016). Again, 
further studies are needed to better assess complication rate and long term efficacy of 
the Woven Endobridge device in treating wide-neck and wide-neck bifurcation 
aneurysms (Caroff et al., 2014). 
The LUNA Aneurysm Embolization System (AES) is a self-expanding ovoid 
device that serves as an intra saccular flow diverter as well as a scaffold for 
endothelization across the neck.  Preliminary results determine a good safety profile and 
the first short-term angiographic follow-up are promising. However, more and longer 
follow-up study results are impending (Kwon et al., 2011). 
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Annex 
 
 
Table 1 : Modified Fisher and Fisher Grading Scale for Subarachnoid Hemorrhage 
Grade Modified 
Fisher 
% of 
Vasospam 
Fisher % of 
Vasospam 
0 No SAH or 
IVH 
   
1 Thin SAH, 
no IVH 
24 No SAH or IVH 21 
2 Thin SAH 
with IVH 
33 Diffuse or thin layer of blood < 1 
mm thick 
25 
3 Thick SAH, 
no IVH 
33 Localized clots and/or layers of 
blood > 1 mm thick in the vertical 
plane 
37 
4 Thick SAH 
with IVH 
40 Localized clots and/or layers of 
blood > 1 mm thick in the vertical 
plane 
31 
 
 
Table 2: Hunt and Hess Grading Scale 
Grade Criteria Index of 
Perioperative 
Mortality (%) 
0 Aneurysm is not ruptured 0 - 5 
I Asymptomatic or with minimal headache and slight nuchal 
rigidity  
0 - 5 
II Moderate to severe headache, nuchal rigidity, but no 
neurologic deficit other than cranial nerve palsy  
2 - 10 
III Somnolence, confusion, medium focal deficits 10 - 15 
IV Stupor, hemiparesis medium or severe, possible early 
decerebrate rigidity, vegetative disturbances 
60 - 70 
V Deep coma, decerebrate rigidity, moribund appearance  70 - 100 
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Table 3: Glasgow Coma Scale 
Eye Opening Points 
Eyes open spontaneously 4 
Eyes open to verbal command 3 
Eyes open only with painful stimuli  2 
No eye opening 1 
Verbal Response Points 
Oriented and converses 5 
Disoriented and converses  4 
Inappropriate words  3 
Incomprehensible sounds 2 
No verbal response  1 
Motor Response Points 
Obeys verbal commands 6 
Response to painful stimuli (UE) 
     Localizes pain 5 
     Withdraws from pain  4 
     Flexor posturing 3 
     Extensor posturing 2 
     No motor response  1 
Total Score = eye opening + verbal + motor 
 GCS < 5:      80 % die or remain vegetative  
 GCS > 11 :   90 % completely recover 
From Teasdale G, Jennett B: Acta Neurochirurg 34:45, 1976 
 
 
 
 
 
 
Table 4:  WFNS Grading Scale 
WFNS Grades GCS Score Motor deficit 
I 15 Absent  
II 14 - 13 Absent 
III 14 - 13 Present 
IV 12 - 7 Present or absent 
V 6 – 3 Present or absent 
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Table 5: WFNS and PAASH - SAH grading scales with criteria per grade and relation with 
outcome 
Scale Grade Criteria 
Proportion of 
patients with 
poor outcome 
OR for poor 
outcome 
WFNS I GCS 15 14-8 % ref 
 II 
GCS 13-14 no 
focal deficits 
29.4 % 2.3 
 III 
GCS 13-14 focal 
deficits 
52.6 % 6.1 
 IV GCS 7-12 58.3 % 7.7 
 V GCS 3-6 92.7 % 69 
PAASH I GCS 15 14.8 % ref 
 II GCS 11-14 41.3 % 3.9 
 III GCS 8-10 74.4 % 16 
 IV GCS 4-7 84.7 % 30 
 V GCS 3 93.9 % 84 
Poor outcome defined as Glasgow outcome scale 1–3 or modified Rankin score 4–6. WFNS = World Federation of Neurological 
Surgeons Grading Scale for Subarachnoid Haemorrhage . PAASH = Prognosis on Admission of Aneurysmal Subarachnoid 
Haemorrhage grading scale. GCS = Glasgow Coma Score. Data in this table are adapted from Steiner et al., 2013 
Table 6: SACE - Advantages and disadvantages 
Stent–assisted coiling of intracranial aneurysms 
Advantages Disadvantages 
 Aneurysms with complex 
morphologies, wide necks or 
unfavorable dome–to–neck ratio 
 More stable access during coil 
placement (‘‘jailing”) 
 Mechanical scaffold for microcoils 
 Allows increased packing density 
 Improved neck coverage 
 Prevention of coil protrusion into 
parent artery 
 Flow diverting properties 
 Facilitate aneurysm thrombosis and 
durability of coil embolization 
 Scaffold for endothelialization and 
growth of fibroelastic tissue at the 
aneurysm neck 
  Potential for infarction secondary to 
vasospasm due to stent 
 Requires antiplatelet therapy 
 External ventricular drain: 
intraparenchyma hematoma risks 
 High likelihood of future invasive 
procedures 
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